Details for Patent: 8,178,693
Which drugs does patent 8,178,693 protect, and when does it expire?
Patent 8,178,693 protects KOSELUGO and is included in two NDAs.
This patent has one hundred and twenty-three patent family members in thirty-four countries.
Summary for Patent: 8,178,693
| Title: | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| Abstract: | Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein A, R1, R2, R7, R8, and R9 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds. |
| Inventor(s): | Eli M. Wallace, Joseph P. Lyssikatos, Allison L. Marlow, T. Brian Hurley |
| Assignee: | Alexion Pharma International Operations Ltd , Array Biopharma Inc |
| Application Number: | US12/824,559 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,178,693 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,178,693
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | KOSELUGO | selumetinib sulfate | CAPSULE;ORAL | 213756-001 | Apr 10, 2020 | RX | Yes | No | 8,178,693 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Astrazeneca | KOSELUGO | selumetinib sulfate | CAPSULE;ORAL | 213756-002 | Apr 10, 2020 | RX | Yes | Yes | 8,178,693 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Astrazeneca | KOSELUGO | selumetinib sulfate | GRANULE;ORAL | 219943-001 | Sep 10, 2025 | RX | Yes | Yes | 8,178,693 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Astrazeneca | KOSELUGO | selumetinib sulfate | GRANULE;ORAL | 219943-002 | Sep 10, 2025 | RX | Yes | No | 8,178,693 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,178,693
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1482932 | ⤷ Start Trial | PA2019007 | Lithuania | ⤷ Start Trial |
| European Patent Office | 1482932 | ⤷ Start Trial | LUC00100 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1482932 | ⤷ Start Trial | 300974 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1482932 | ⤷ Start Trial | 2019C/510 | Belgium | ⤷ Start Trial |
| European Patent Office | 1482932 | ⤷ Start Trial | CA 2019 00011 | Denmark | ⤷ Start Trial |
| European Patent Office | 1482932 | ⤷ Start Trial | C20190010 00281 | Estonia | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
